Roche sceptical about investing more in 'guided-missile' ADC cancer drugs
Roche was an early ADC pioneer with the drugs Kadcyla and Polivy but was disappointed by the outcome of further development efforts in the field.
Mannheim: Roche remains sceptical about investing more in the field of antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs due to their precision, even as the field attracts heightened attention in the pharmaceutical industry."There are quite a few companies that invest in this area. As for us, we still have rather limited interest," Chief Executive...
Login or Register to read the full article
Mannheim: Roche remains sceptical about investing more in the field of antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs due to their precision, even as the field attracts heightened attention in the pharmaceutical industry.
"There are quite a few companies that invest in this area. As for us, we still have rather limited interest," Chief Executive Severin Schwan told journalists at a briefing.
The Swiss group's CEO declined to comment when asked about any takeover interest in ADC specialist Seagen Inc which, according to a Wall Street Journal report last week, has attracted Merck & Co and other rival drugmakers as potential suitors.
Roche was an early ADC pioneer with the drugs Kadcyla and Polivy but was disappointed by the outcome of further development efforts in the field.
Elsewhere, however, a recent drug trial success underscored the prospects of AstraZeneca and Daiichi Sankyo's ADC Enhertu as a potential multi-billion seller
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd